Skip to Content

Ranexa Approval History

  • FDA approved: Yes (First approved January 27th, 2006)
  • Brand name: Ranexa
  • Generic name: ranolazine
  • Dosage form: Extended-Release Tablets
  • Company: CV Therapeutics, Inc.
  • Treatment for: Angina

Ranexa (ranolazine) is an antianginal and anti-ischemic agent indicated for the treatment of chronic angina.

Development History and FDA Approval Process for Ranexa

Nov  6, 2008Approval FDA Approves Ranexa for First Line Anti Anginal Use
Dec 19, 2007Approval FDA Approves New Mechanism of Action Labeling for Ranexa
Aug 14, 2007Approval CV Therapeutics Launches 1000 mg Ranexa Tablet
Jan 27, 2006Approval Ranexa Approved - CV Therapeutics, Inc. - Treatment for Chronic Angina
Jul 27, 2005CV Therapeutics Submits Amendment to Ranexa (ranolazine)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.